Belite Bio, Inc – NASDAQ:BLTE
Belite Bio stock price today
$61.5
-0.5
-0.81%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Belite Bio stock price monthly change
+26.12%
month
Belite Bio stock price quarterly change
+26.12%
quarter
Belite Bio stock price yearly change
+34.72%
year
Belite Bio key metrics
Market Cap | 1.99B |
Enterprise value | N/A |
P/E | -46.59 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 14.24 |
PEG ratio | 0.68 |
EPS | -1.19 |
Revenue | N/A |
EBITDA | -34.57M |
Income | -33.66M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBelite Bio stock price history
Belite Bio stock forecast
Belite Bio financial statements
| Sep 2023 | 0 | -10.93M | |
|---|---|---|---|
| Dec 2023 | 0 | -6.99M | |
| Mar 2024 | 0 | -7.87M | |
| May 2024 | 0 | -7.87M |
| Aug 2025 | 0 | -8.01M | |
|---|---|---|---|
| Sep 2025 | 0 | -5.66M | |
| Dec 2025 | 0 | -8.01M | |
| Dec 2025 | 0 | -6.22M |
Analysts Price target
Financials & Ratios estimates
| 2023-05-10 | -0.17 | -0.33 |
|---|
| Sep 2023 | 57598000 | 4.80M | 8.34% |
|---|---|---|---|
| Dec 2023 | 94642000 | 4.21M | 4.45% |
| Mar 2024 | 101147000 | 4.67M | 4.62% |
| May 2024 | 101147000 | 4.67M | 4.62% |
| Jun 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
| Mar 2024 | 0 | 0 | 0 |
Belite Bio alternative data
| Aug 2023 | 5 |
|---|---|
| Sep 2023 | 5 |
| Oct 2023 | 5 |
| Nov 2023 | 5 |
| Dec 2023 | 5 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Belite Bio other data
4.15%
-4.81%
of BLTE is owned by hedge funds
829.06K
-28.26K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 13 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Belite Bio stock today?
One share of Belite Bio stock can currently be purchased for approximately $61.5.
-
When is Belite Bio's next earnings date?
Unfortunately, Belite Bio's (BLTE) next earnings date is currently unknown.
-
Does Belite Bio pay dividends?
No, Belite Bio does not pay dividends.
-
How much money does Belite Bio make?
Belite Bio has a market capitalization of 1.99B. Belite Bio made a loss 31.63M US dollars in net income (profit) last year or -$0.33 on an earnings per share basis.
-
What is Belite Bio's stock symbol?
Belite Bio, Inc is traded on the NASDAQ under the ticker symbol "BLTE".
-
What is Belite Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Belite Bio?
Shares of Belite Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Belite Bio have?
As Jul 2024, Belite Bio employs 20 workers.
-
When Belite Bio went public?
Belite Bio, Inc is publicly traded company for more then 3 years since IPO on 29 Apr 2022.
-
What is Belite Bio's official website?
The official website for Belite Bio is belitebio.com.
-
Where are Belite Bio's headquarters?
Belite Bio is headquartered at 5820 Oberlin Drive, San Diego, CA.
-
How can i contact Belite Bio?
Belite Bio's mailing address is 5820 Oberlin Drive, San Diego, CA and company can be reached via phone at 858-246-6240.
Belite Bio company profile:
Belite Bio, Inc
belitebio.comExchange:
NASDAQ
Full time employees:
20
Industry:
Biotechnology
Sector:
Healthcare
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
5820 Oberlin Drive
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001889109
ISIN: US07782B1044
CUSIP: 07782B104
